Leap Therapeutics History

 Our History

First patient dosed with TRX518 001

Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518

Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518

First patient dosed with TRX518 001

Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518

Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518

Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518

 
 

Team

Luke Andersen
Finance
Lianna Cohen
Clinical
Liliana Cygan
Clinical
Michael Haas, Ph.D.
 Research
Peter Hocknell, Ph.D.
Manufacturing
Michael Kagey, Ph.D.
 Research
Reena Lynam
Clinical
Sri Kolluri_WebsitePic.JPG
Sri Kolluri
Clinical
Cliff Kwityn
Manufacturing
gus lawlor 2.PNG
Gus Lawlor
Chief Operating Officer
Matthew Lederhos
Finance
Chris Cropped.jpg
Capture walter.PNG
Jonathan Miller
Business Development
Chris Mirabelli, Ph.D.
Chairman of the Board
Walter Newman, Ph.D.
Senior Research Fellow
Alyssa Nicotra
Clinical
Mark.jpg
Doug Onsi.jpg
Mark O'Mahony
Chief Manufacturing Officer
Douglas Onsi
President & CEO
Diane Piper
Clinical
cyndi1.jpg
Robert Steinberg
Operations
Cyndi Sirard, M.D.
Chief Medical Officer
Katie Woolford

Clinical

2006

2009

First US patent filed for TRX518 

First patient dosed with DKN-01 by Eli Lilly 

2010

First patient dosed with TRX518 at Memorial Sloan Kettering Cancer Center 

2010

First US patent granted covering sequence of DKN-01 

2016

Leap Therapeutics launched

2017

Leap Therapeutics becomes publicly listed on NASDAQ: LPTX 

2017

Initiated collaboration with Merck to evaluate DKN-01 in combination with Keytruda 

2018

Initiated collaboration with Pfizer/Merck KGaA to evaluate TRX518 in combination with Bavencio 

2020

Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01

2020

Leap Therapeutics Announces Orphan Drug Designation of DKN-01 for the Treatment of Gastric/Gastroesophageal Junction Cancer and Closes $45 million Public Offering of Common Stock

Board of Directors

Chris Mirabelli, Ph.D.
Chairman of the Board, Leap Therapeutics

Thomas Dietz, Ph.D.

Chairman and CEO of Waypoint Holdings

Doug Onsi, J.D.
President & CEO, Leap Therapeutics

Nissim Mashiach

Co-Founder of NuBiyota 

James Cavanaugh, Ph.D.
Managing Director at HealthCare Ventures

William Li, M.D.

CEO and President of Angiogenesis Foundation

Joseph Loscalzo, M.D., Ph.D, M.A.

Chairman, Department of Medicine, Physician-in-Chief, Brigham and Women’s Hospital

Monica M. Bertagnolli, MD, FASCO

Chief, Division of Surgical Oncology, Dana-Farber/Brigham and Women's Cancer Center; Professor of Surgery, Harvard Medical School, Boston

 
 

Scientific Advisory Board

David Tuveson, M.D., Ph.D.
Chair of Leap SAB, Director of Research, the Lustgarten Foundation, Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory

Xi He, Ph.D.

Endowed Research Chair, Professor of Neurology, American Cancer Society Research Professor, Boston Children’s Hospital and Harvard Medical School
 

Wendy S. Garrett, M.D., Ph.D.

Professor of Immunology and Infectious Disease at the Harvard T.H. Chan School of Public Health and Associate Professor of Medicine at Harvard Medical School. Physician at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA

Carl F. Nathan, M.D.

Professor and Chairman of Department of Microbiology and Immunology at Weill Cornell Medical College
 

Eric P. Winer, M.D.

Senior Vice President and Chief Clinical Strategy Officer; Chief, Division of Women's Cancers, Dana Farber Cancer Institute; Director, Breast Oncology Program, Susan F. Smith Center for Women's Cancers; Thompson Chair in Breast Cancer Research Institute Physician; Professor of Medicine, Harvard Medical School
 

Twiter Icon.png

© 2019 Leap Therapeutics, Inc.       All Rights Reserved